A Case Treated with Extracorporeal Membrane Oxygenation for Disseminated Cytomegalovirus Infection after Liver Transplantation

Jimyung Park, M.D.¹, Yoon Hyun Lee, M.D.², Young Rok Choi, M.D.², Yeon Joo Lee, M.D.¹, Dong Jung Kim, M.D.³, Sanghoon Jheon, M.D.³ and Young-Jae Cho, M.D.¹

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine¹, Departments of Surgery², Thoracic and Cardiovascular Surgery³, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

Cytomegalovirus (CMV) is a clinically important pathogen in immunocompromised patients, especially after organ transplantation. However, there have been several reports of severe CMV infections in immunocompetent patients. This report presents a case of an immunocompetent patient who presented with fulminant hepatitis requiring liver transplantation. Because CMV was detected upon histopathologic review of the explanted liver, it was later assumed that CMV may be the primary cause of hepatitis. However, at the time of transplantation, we did not suspect CMV hepatitis. Following transplantation and initiation of immunosuppression, the patient developed viral sepsis with a disseminated CMV infection. Respiratory failure because of CMV pneumonia worsened despite antiviral therapy, and venovenous extracorporeal membrane oxygenation (ECMO) was initiated. Although ECMO has been traditionally contraindicated in patients with sepsis, this patient recovered and was successfully weaned off ECMO. CMV should be included in the differential diagnosis of fulminant hepatitis, even in immunocompetent patients, especially when liver transplantation is considered.

Key Words: Cytomegalovirus, Extracorporeal membrane oxygenation, Liver transplantation, Sepsis

대표 단어: 거대세포바이러스, 체외막산소공급, 간이식, 패혈증

INTRODUCTION

Cytomegalovirus (CMV) is an important pathogen that can cause severe disease in immunocompromised patients and it is the single most common viral pathogen complicating organ transplantation. In immunocompromised patients, CMV can cause a wide variety of diseases depending on the organ involved, including esophagitis, enterocolitis, hepatitis, pneumonia, retinitis, and encephalitis(1).

In contrast, in immunocompetent patients, CMV infection usually presents as a benign, self-limited disease. It most commonly manifests as a heterophile antibody-negative mononucleosis syndrome. However, there have been several reports of severe CMV infection in immunocompetent patients, among which involvement of gastrointestinal tract and central nervous system were the most common(2). Abnormal liver function tests (LFTs) are frequently associated with a self-limited CMV infection but fulminant CMV hepatitis is rare(3).

As cell-mediated immunity plays a critical role in the host defense against CMV, the clinical manifestations of CMV infection may worsen if immunosuppressive agents are prescribed without the proper diagnosis and treatment of CMV. Here we report a case of fulminant hepatitis, initially of un-
known origin, requiring liver transplantation. After transplantation and histopathologic review of the explanted liver, it was assumed that CMV may be the primary cause of hepatitis. In fact, CMV was not diagnosed before transplantation and immunosuppression was initiated without antiviral therapy. Consequently, the virus disseminated to the lung causing severe respiratory failure.

Extracorporeal membrane oxygenation (ECMO) is a life support technology that is used for respiratory or cardiac failure refractory to conventional treatment(4). Owing to rapid technical improvements, the use of ECMO has been dramatically increasing over the last decade(5). ECMO was traditionally contraindicated in cases of sepsis or severe infection due to the concern for infecting the circuit(6,7). It is still controversial as to whether ECMO can be useful in septic conditions and data on the clinical outcomes of ECMO in viral sepsis, including CMV infection, are especially scarce. Currently, there are no reports on ECMO for CMV infection. In fact, there is mounting evidence that CMV infection leads to a hypercoagulable state and unprovoked thrombosis, which can be problematic during extracorporeal therapy(8).

Although there was limited evidence of its effect, we initiated ECMO in this patient because her respiratory failure progressed to a refractory state, despite the use of antiviral therapy and mechanical ventilation. The patient recovered well and was successfully weaned off ECMO. This case emphasizes the importance of considering CMV as a cause of fulminant hepatitis when other common etiologies of hepatitis have been ruled out. In addition, this case proposes a possible role of ECMO in treating severe viral pneumonia in an immunocompromised patient.

CASE REPORT

A 56-year-old woman, without previous liver disease, was admitted for jaundice, which had developed 3 weeks prior to admission. She had been on medication for hypertension and dyslipidemia for years, but denied any history of exposure to other new drugs, including herbal medications. Initial laboratory results revealed abnormal LFTs: the levels of aspartate transaminase, alanine transaminase, and bilirubin were 1,463 IU/L, 801 IU/L, and 38.2 mg/dL, respectively, and her international normalized ratio for prothrombin time was 2.20. Serological test results for hepatitis A, B, and C virus were all negative. The test results for autoimmune antibodies, including antinuclear antibody and antimitochondrial antibody, were also negative. To determine the cause of hepatitis, a percutaneous liver biopsy was performed and the histopathology showed portal inflammatory cell infiltration and bile duct damage, which are consistent with an acute hepatitis. However, no specific etiology was identified.

In spite of conservative management for acute hepatitis, her liver function showed no improvement. In spite of the lack of clinical evidence, the possibility of autoimmune hepatitis or toxic hepatitis was considered and high-dose corticosteroids were administered, but there was no response. Hepatorenal syndrome rapidly progressed and symptoms of hepatic encephalopathy started to appear. Her urine output decreased, followed by the development of a metabolic acidosis. The hepatic encephalopathy worsened and the patient progressed into a comatose state. At 3 weeks after admission, she was transferred to the medical intensive care unit (ICU) and continuous renal replacement therapy (CRRT) was initiated. At the same time, she was registered for deceased donor liver transplantation and placed on the waiting list of candidates.

On the 2nd day of her ICU admission, a matched deceased donor was found in the Korean Network for Organ Sharing and the patient underwent liver transplantation. After transplantation, LFT abnormality and azotemia rapidly improved to near normal ranges. Her mental status recovered to an alert state. CRRT was stopped and she was successfully extubated on postoperative day (POD) 2.

For immunosuppression, high doses of corticosteroids (initially 200 mg/day and tapered to 20 mg/day), tacrolimus (initially 2 mg/day and adjusted to target blood trough concentration around 10 ng/mL), mycophenolate mofetil (1,000 mg/day), and basiliximab (20 mg on the day of transplantation, followed by a second dose 4 days after transplantation) were administered according to the protocol at our center.

Results of pre-transplantation serological test showed that both recipient and donor were seropositive for CMV. In such cases, our center uses preemptive therapy with serial follow-up with a CMV antigenemia assay (every 2 weeks
until 3 months after transplantation)(9). We typically consider antiviral therapy for CMV when the CMV antigenemia assay shows over 10 infected cells per 200,000 leukocytes in the peripheral blood. For prophylaxis of *Pneumocystis jirovecii* and fungal infection, we prescribed trimethoprim/sulfamethoxazole and fluconazole, respectively.

On POD 5, she had an acute onset of fever with bilateral lung opacities on chest radiographs (Fig. 1A) and required oxygen therapy for desaturations. As hypoxic respiratory failure developed, LFT abnormalities developed again with a pattern consistent with hepatocellular injury: serum aspartate transaminase and alanine transaminase levels were elevated up to 801 and 343 IU/L, respectively. Her fever persisted and her blood pressure began to drop, requiring nor-epinephrine and dopamine infusion. Blood cultures were obtained and we empirically prescribed broad spectrum antibiotics. However, no microorganism was identified on blood culture. Although CMV antigenemia assay is typically performed after 2 weeks of transplantation at our center, it was performed earlier than planned for this patient in order to rule out a CMV infection.

On POD 7, since there was no response to empirical antibiotic therapy, we performed a biopsy of the transplanted liver in order to identify the cause of the newly deteriorating liver function. A type 1 respiratory failure also rapidly progressed with no improvement in chest radiographs (Fig. 1B) and mechanical ventilation was restarted. After intubation, a bronchoscopy was performed in order to search for infectious causes of respiratory failure. We examined the bronchialveolar lavage (BAL) fluid for several microorganisms. On that day, the result of CMV antigenemia assay showed 235 infected cells per 200,000 leukocytes in the peripheral blood and we started an induction dose of ganciclovir (5 mg/kg every 12 hours).

The liver biopsy specimen, which was obtained on POD 7, showed multifocal necrosis with some hepatic cytoplasmic inclusions and an immunohistochemical staining for CMV was positive (Fig. 2). From the BAL fluid, polymerase chain reaction for CMV and CMV culture were found to be positive as well. We did not per-
form a transbronchial lung biopsy because the patient’s ventilatory status was unstable. Other than CMV, neither bacteria nor fungus was identified on the examination of the BAL fluid. Based on the results of the above tests, we diagnosed the patient with disseminated CMV infection involving the lung and liver(10).

Although ganciclovir was started, there was no immediate clinical improvement. Pneumonia did not subside rapidly and hypoxia was not corrected on the mechanical ventilator. Hypoxia was refractory to all attempted therapies including lung-protective ventilation, high positive end-expiratory pressure (PEEP), and inhaled nitric oxide. Arterial blood gas analysis showed an arterial partial oxygen pressure ($PaO_2$) of 55 mmHg with a fraction of inspired oxygen ($FiO_2$) of 100%, PEEP of 12 cm H$_2$O, and inhalation of 20-ppm nitric oxide. Although she was hypotensive, echocardiography showed preserved cardiac function with an ejection fraction of 63%. Therefore, we decided to initiate venovenous ECMO for refractory respiratory failure on POD 10.

Two 21-French venous cannulas (Bio-Medicus, Medtronic Inc., Minneapolis, MN, USA) were placed into the right and left femoral veins for inflow and outflow, respectively (Fig. 1C). We used the PLS system (MAQUET GmbH, Rastatt, Germany). The procedure was performed at the bedside in the ICU under maximal sterile barrier precautions. ECMO was initiated with a circuit flow of 4.5 L/min and a sweep gas flow of 3 L/min of oxygen (100% $FiO_2$). After ECMO initiation, the ventilator settings were changed to the minimum levels. The PEEP was 10 cm H$_2$O and the peak inspiratory pressure was 25 cm H$_2$O, resulting in a tidal volume ranging from 150 to 200 mL. The $FiO_2$ setting of the ventilator was still maintained at 100% because of the hypoxia. Resultant arterial blood gas analysis revealed a $PaO_2$ of 75 mmHg and arterial partial carbon dioxide pressure ($PaCO_2$) of 42 mmHg. Her oxygen saturation remained in the range of 90% to 95% as estimated using pulse oximetry. We started anticoagulation therapy with heparin, but stopped after 5 days because of a prolonged prothrombin time with LFT aggravation. Subsequently, we maintained ECMO without any anticoagulation.

We continued the administration of ganciclovir and minimized the level of immunosuppression. On POD 16, 6 days after the initiation of ECMO, a negative result on the CMV antigenemia assay was achieved. Her radiographic findings and LFTs also began to improve. On POD 23, 13 days after ECMO, given the dramatic improvement in her radiographic findings and oxygenation status, we decided to wean her off ECMO. We changed the sweep gas flow to zero and the patient’s oxygenation status was well maintained with mechanical ventilator support only ($FiO_2$ 70%, PEEP 7 cm H$_2$O, peak inspiratory pressure 23 cm H$_2$O). She was successfully
weaned off ECMO, and on POD 28, 5 days after weaning from ECMO, was also taken off the mechanical ventilator. After a 3-week course of an induction dose of ganciclovir, antiviral therapy was changed to a maintenance dose of valganciclovir (900 mg daily). She was discharged and the maintenance antiviral therapy was continued for 3 months. Eighteen months after transplantation, she was doing well with no rejection. Follow-up radiographs showed no definitive sequelae (Fig. 1D).

After the patient recovered, we investigated the explanted liver again to elucidate the primary cause of initial fulminant hepatitis. The histopathology showed submassive hepatic necrosis and immunohistochemistry revealed a few cells that were positive for CMV. Therefore, in this case, it can be assumed that the delayed diagnosis of the initial CMV hepatitis and liver transplantation without proper antiviral therapy resulted in CMV dissemination. A brief timeline of the clinically important diagnostic and therapeutic procedures is shown in Fig. 3.

**DISCUSSION**

CMV is an important pathogen in immunocompromised patients and critically ill patients. It is also the single most common viral pathogen complicating organ transplantation, including liver transplantation(11). However, CMV can also cause severe diseases in immunocompetent patients, as illustrated by this case. In a previous systematic review about severe CMV infection in immunocompetent patients, colitis was the most common manifestation and hepatitis was rare(2). However, there have been a few reports of fulminant CMV hepatitis(12,13). Since CMV was only detected in the explanted liver, but not in the initial percutaneous liver biopsy, it is not clear if the initial hepatic failure resulted solely from a CMV infection. Because empirical corticosteroids for a presumed autoimmune hepatitis were administered before transplantation, it might have caused a reactivation of the CMV. However, since there was no clinical evidence of an autoimmune hepatitis and the patient denied any history suspicious of toxic hepatitis, we assumed that initial culprit was CMV.

After organ transplantation, an allograft is the most common site for organ involvement of CMV. For example, CMV hepatitis is the most common manifestation of a CMV infection after liver transplantation(11). However, the involvement of multiple organs is possible, as illustrated by this case. In this case, although the infected liver was explanted, immunosuppression after transplantation was thought to have resulted in the dissemination of CMV. In addition to immunosuppression, combined renal failure and corticosteroid therapy before transplantation might have had a synergistic effect, impairing cell-mediated immunity significantly.

In this case, we used venovenous ECMO for the treatment of respiratory failure due to CMV pneumonia. Despite the increased use of ECMO in critically ill patients, there is a lack of evidence regarding whether ECMO can be useful in patients with sepsis. Historically, sepsis was considered a contraindication to ECMO(6,7). However, sepsis is a common cause of acute respiratory distress syndrome and shock, requiring extracorporeal therapy. The reported outcomes of ECMO in adult patients with sepsis are variable(14-16). It
is postulated that venoarterial ECMO could be helpful in sepsis patients with severe cardiac dysfunction, but there is still minimal experience with adult patients(16). Furthermore, the current data available are mostly limited to bacterial sepsis and there are few reports regarding ECMO in severe viral infection. The pathophysiology of viral sepsis is less certain than bacterial sepsis and the role of ECMO in viral sepsis is unclear yet(17).

In our case, the patient was successfully weaned from ECMO without significant complications and, as far as we know, this is the first report of the use of ECMO for the treatment of CMV pneumonia. It is well-known that CMV infection leads to a hypercoagulable state and there have been many reports of thrombosis associated with a CMV infection(8,18). Although the role of anticoagulation may be less important in venovenous ECMO compared to venoarterial ECMO, thromboembolism remains a major concern in ECMO. Therefore, in theory, CMV infection may not be a good indication for ECMO. In this case, there was no clinically significant thromboembolism or circuit obstruction even though anticoagulation was suspended early. Thrombosis might have been prevented because of the concomitant coagulopathy caused by the liver dysfunction in our patient.

Despite the major technological advancements, ECMO is still associated with considerable complications and costs. It is necessary to choose the appropriate patients who may benefit from ECMO. Although patients with viral pneumonia were reported to have a favorable prognosis when ECMO was used, the evidence is largely limited to influenza pneumonia and data pertaining to other viral pneumonias are scarce(19). More data are needed to establish the role of ECMO in viral pneumonia(20). On the other hand, an immunocompromised state was reported to be significantly associated with poor outcomes in ECMO(19). However, ECMO can be life-saving even if the patient is immunocompromised, as in our case, when a high level of expertise and intensive support are available.

In conclusion, this report presents a case of fulminant CMV hepatitis, requiring liver transplantation, which was followed by a disseminated infection involving the lung, after transplantation. CMV pneumonia progressed to a refractory respiratory failure, but it was successfully treated with venovenous ECMO and antiviral therapy. We suggest that CMV should be suspected as a possible cause of hepatitis when other common etiologies are ruled out and especially when transplantation is considered. In addition, as shown in this case, ECMO can be a life-saving tool even for immunocompromised patients.

REFERENCES

1) Nguyen Q, Estey E, Raad I, Rolston K, Kantarjian H, Jacobson K, et al. Cytomegalovirus pneumonia in adults with leukemia: an emerging problem. Clin Infect Dis 2001;32:539-45.
2) Rafailidis PI, Mourtzoukou EG, Varbobitis IC, Falagas ME. Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J 2008;5:47.
3) Wreghitt TG, Teare EL, Sule O, Devi R, Rice P. Cytomegalovirus infection in immunocompetent patients. Clin Infect Dis 2003;37:1603-6.
4) Brodie D, Baccetta M. Extracorporeal membrane oxygenation for ARDS in adults. N Engl J Med 2011;365:1905-14.
5) Karagiannidis C, Brodie D, Strassmann S, Stolzen F, Philipp A, Bein T, et al. Extracorporeal membrane oxygenation: evolving epidemiology and mortality. Intensive Care Med 2016;42:889-96.
6) Hanke F, Schildhauer TA, Schlebes AD, Strauch JT, Swol J. Infections and extracorporeal membrane oxygenation: incidence, therapy, and outcome. ASAIO J 2016;62:620-6.
7) Muller T, Lubnow M, Philipp A, Schneider-Brachert W, Camboni D, Schmid C, et al. Risk of circuit infection in septic patients on extracorporeal membrane oxygenation: a preliminary study. Artif Organs 2011;35:E84-90.
8) Squizzato A, Gerdes VE, Buller HR. Effects of human cytomegalovirus infection on the coagulation system. Thromb Haemost 2005;93:403-10.
9) Kotton CN, Kumar D, Callen AM, Asberg A, Chou S, Danziger-Isakov L, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013;96:333-60.
10) Liungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094-7.
11) Lee SO, Razonable RR. Current concepts on cytomegalovirus infection after liver transplantation. World J Hepatol 2010;2:325-36.
12) Yu YD, Park GC, Park PJ, Choi YI, Hwang S, Song GW, et al. Cytomegalovirus infection-associated fulminant hepatitis in an immunocompetent adult requiring emergency living-donor liver transplantation: report of a case. Surg Today 2013;43:424-8.
13) Shusterman NH, Frauenhoffer C, Kinsey MD. Fatal massive hepatic necrosis in cytomegalovirus mononucleosis. Ann Intern Med 1978;88:810-2.
14) Huang CT, Tsai YJ, Tsai PR, Ko WJ. Extracorporeal membrane oxygenation resuscitation in adult patients with refractory septic shock. J Thorac Cardiovasc Surg 2013;146:1041-6.
15) Cheng A, Sun HY, Lee CW, Ko WJ, Tsai PR, Chuang YC, et al. Survival of septic adults compared with nonseptic adults receiving extracorporeal membrane oxygenation for cardiopulmonary failure: a propensity-matched analysis. J Crit Care 2013;28:532.e1-10.
16) Brechot N, Luyt CE, Schmidt M, Leprince P, Trouillet JL, Leger P, et al. Venoarterial extracorporeal membrane oxygenation support for refractory cardiovascular dysfunction during severe bacterial septic shock. Crit Care Med 2013;41:1616-26.
17) Steinberg BE, Goldenberg NM, Lee WL. Do viral infections mimic bacterial sepsis? The role of microvascular permeability: a review of mechanisms and methods. Antiviral Res 2012;93:2-15.
18) Justo D, Finn T, Atzmony L, Guy N, Steinvil A. Thrombosis associated with acute cytomegalovirus infection: a meta-analysis. Eur J Intern Med 2011;22:195-9.
19) Schmidt M, Bailey M, Sheldrake J, Hodgson C, Aubron C, Rycus PT, et al. Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure. The Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score. Am J Respir Crit Care Med 2014;189:1374-82.
20) Jain S, Self WH, Wunderink RG, Fakhour S, Balk R, Bramley AM, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 2015;373:415-27.